^
Association details:
| Biomarker: | PTGS2 expression |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | Xpovio (selinexor) (XPO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nuclear Export Inhibition for Radiosensitization; a Proof-of-Concept Phase I Clinical Trial of Selinexor (KPT-330) Combined with Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Published date:
03/06/2022
Excerpt:
A phase I clinical trial of selinexor plus ChRT for LARC was performed, 3+3 design...Patients received 50.4 Gy over 5.5 weeks plus capecitabine 825 mg/m2 twice daily on radiation days. Of the 9 patients who completed treatment, median volumetric tumor shrinkage was 93% (IQR 59-98). Comparing baseline clinical stage to final pathological stage, 82% of patients were down-staged. Two patients experienced a complete / near-complete pathological response. Expression of PTGS2 and CD177 were identified as potential biomarkers of response.
Secondary therapy:
capecitabine
DOI:
10.1016/j.ijrobp.2022.05.026
